Posted by Michael Wonder on 12 Jan 2025
BridgeBio Oncology Therapeutics granted US FDA fast track designation for BBO-8520 for KRASG12C mutated metastatic non-small cell lung cancer
9 January 2025 - The US FDA has granted fast track designation to BBO-8520 for the treatment of adult patients with previously treated, KRASG12C mutated metastatic non-small cell lung cancer.
BBO-8520 is currently being evaluated in the ONKORAS-101 trial, a Phase 1 study for patients with KRASG12C mutant non-small cell lung cancer.
